Sean Maduck, the president of Corcept Endocrinology, has executed a sale of company stock valued at approximately $4.9 million. This transaction reflects a significant financial move within the company’s leadership. Details regarding the specific number of shares sold or the intended use of the proceeds from the sale have not been disclosed. The sale is part of standard practices among executives managing their personal investment portfolios.
Related Articles
Don't miss out on breaking stories and in-depth articles.